1. Introduction {#sec1}
===============

Obesity is now regarded as a disease of epidemic proportions in the United States. Data from the National Health and Nutrition Examination Survey (NHANES) demonstrate that the prevalence of overweight in children and adolescents has been rising at a staggering rate during the last several decades \[[@B1], [@B2]\]. The 2003-to-2004 survey indicated that approximately 17 percent of children and adolescents aged 2 to 19 years were overweight. This represents a dramatic increase from the NHANES III (1988 to 1994) overweight figure of 11 percent. The finding that overweight children are at risk of becoming overweight adults \[[@B3]\] is especially concerning given that overweight adults have elevated risks of developing metabolic and cardiac disorders \[[@B4]\]. In particular, abdominal obesity has been linked to serious morbidities, such as diabetes mellitus \[[@B5]\], heart disease \[[@B6]\], and certain cancers \[[@B7]\]. The health implications of childhood overweight have served as an impetus for major public health concern in the United States.

In adults, obesity and overweight are independent risk factors for gastroesophageal reflux disease (GERD) and endoscopy-proven esophageal erosions \[[@B8]\]. Adults with chronic GERD are at risk of developing associated complications, such as erosive esophagitis \[[@B9]\], Barrett\'s esophagus \[[@B10]\] and adenocarcinoma of the esophagus \[[@B11]\]. There is a growing body of evidence that illustrates the association between increasing body mass index (BMI) and GERD. Cross-sectional studies and meta-analyses have confirmed this association in adult subjects \[[@B12], [@B13]\]. A few studies have established a clear dose-dependent relationship between increasing BMI and GERD symptoms \[[@B8], [@B14], [@B15]\]. Similar data in the pediatric literature are sparse. A study published by Størdal et al. in 2006 demonstrated an association between increasing BMI and GERD in children aged 7 to 16 years, as reported by symptoms or pH monitoring abnormalities \[[@B16]\]. A recent retrospective review by Elitsur et al. did not reveal a greater prevalence of RE in children who were overweight or obese compared to those with normal weight \[[@B17]\]. In this study, we evaluated the association between RE and overweight in children, instead of clinical symptoms or endoscopic findings consistent with GERD. A study published by Zentilin et al. in 2005 showed that histology could provide useful and objective additional data in patients with nonerosive reflux disease \[[@B18]\]. Furthermore, Lombardi et al. suggested that esophageal biopsies are very important aids in the diagnosis of esophagitis since clinical symptoms of GERD or endoscopic visual findings do not always correlate with histologic abnormalities \[[@B19]\].

2. Patients and Methods {#sec2}
=======================

2.1. Patients {#sec2.1}
-------------

A retrospective chart review of all patients between the ages of 2 and 20 years who underwent upper endoscopies with biopsies at New York Weill Cornell Medical Center between January 2000 and April 2006 was carried out. The following exclusion criteria were used: (1) procedures with absence of esophageal biopsies, (2) repeated upper endoscopies on already-included subjects, (3) unavailability of all required information (e.g., anthropometric data at the time of procedure), and (4) subjects with BMI \<5% ile. Charts were reviewed for the following data: age, gender, weight, height, indication for the procedure, presence of RE, and usage of antireflux medications (proton pump inhibitors or H~2~ receptor antagonists) at the time of the procedure for at least 10 days. Weight and height were used to calculate BMI percentiles on 2000 Centers for Disease Control sex-specific BMI-for-age growth charts, which define BMI ≥ 95th percentile to be overweight and BMI ≥ 85th percentile and \< 95th percentile to be at risk for overweight \[[@B20]\]. BMI ≥ 85th percentile was classified as overweight for the purpose of this study. Age- and gender-specific *z*-scores for weight and BMI were calculated. Two hundred thirty patients were included in this study, and detailed characterization and analysis of these subjects (M  :  F = 114  :  116) were conducted. The mean age of the study sample was 11.3 years. The indication for the procedures in order of prevalence was as follows: recurrent abdominal pain (*n* = 151, 65.6%), clinical GERD symptoms (*n* = 51, 22.2%), weight loss (*n* = 18, 7.8%), conditions such as upper GI bleeding or IBD surveillance (*n* = 8, 3.5%), and suspected allergic gastrointestinal disorders (*n* = 2, 0.9%).

2.2. Endoscopy and Biopsy {#sec2.2}
-------------------------

All endoscopies were performed using video gastroscopes (Pentax, Japan) EG1840, EG2430, or EG2731. Biopsy specimens were taken from the gastric antrum and distal esophagus during the procedure. The specimens were immediately fixed in 10% buffered formalin solution, embedded in paraffin, cut at 4--6 microns thick, and stained with hematoxylin-eosin (H&E) for histologic evaluation. A diagnosis of RE was based on histologic findings of basal cell hyperplasia with eosinophilic exocytosis (in the absence of such findings in the upper esophagus). All esophageal biopsy slides were reevaluated by a single pathologist, for grading of the esophagitis using a modification of the scale suggested by Zentilin et al. \[[@B18]\]. Biopsy specimens were graded on a 4-point scale; 0/3 = normal, no basal cell hyperplasia, minimal (less than 3 eosinophils/high power field (HPF) exocytosis; 1/3 = mild (up to 1/3 of epithelial thickness) basal cell hyperplasia, minimal to mild (between 2 and 8 eosinophils/HPF) exocytosis (mild active esophagitis); 2/3 = moderate (from 1/3 to 2/3 of epithelial thickness) basal cell hyperplasia, moderate (between 10 and 15 eosinophils/HPF) exocytosis (moderate active esophagitis); 3/3 = marked (2/3 to full-thickness) basal cell hyperplasia, marked (over 20 eosinophils/HPF) exocytosis (severe active esophagitis) \[[@B21]\].

The study was approved by the Institutional Review Board of Weill Medical College of Cornell University.

3. Statistics {#sec3}
=============

Comparisons between groups were performed using the uncertainty coefficient. *P*-value of \<.05 was accepted as indicating statistical significance. All statistical analyses were performed using commercially available computer software (SPSS for Windows).

4. Results {#sec4}
==========

A total of 230 subjects were included in the study ([Table 1](#tab1){ref-type="table"}). The mean age was 11.3 years (s.d. = 4.7 years), and 114 (49.6%) were male. Forty-two percent of the subjects were between 2 and 10 years of age and 58% from 11 to 20 years. A total of 163 subjects were classified as normal BMI (70.9%), 29 as at risk for overweight (12.6%), and 38 as overweight (16.5%); therefore 67 (29.1%) were defined as overweight. Symptoms of clinical GERD were the indication for endoscopy in 22.2% of subjects. Histologic evidence of RE was seen in 24.3% of subjects. The majority of subjects in this study (129, 56.1%) were on antireflux therapy at the time of endoscopy.

As evident in [Table 2](#tab2){ref-type="table"}, the prevalence of RE in the overweight group did not differ significantly from that in the normal weight group (23.9% versus 24.5%, resp.). Overweight subjects taking antireflux medications demonstrated a higher prevalence of biopsy-proven RE compared to overweight subjects not taking antireflux medications (34.1% versus 7.7%, *P* = .009), as seen in [Table 3](#tab3){ref-type="table"}.

A secondary analysis based on age ([Table 4](#tab4){ref-type="table"}) comparing prepubertal subjects (2 to 10 years) to older subjects (11 to 19 years) showed that the younger subjects had a higher prevalence of both RE (32.0% versus 18.8%, *P* = .022) and overweight (38.1% versus 22.6%, *P* = .010).

5. Discussion {#sec5}
=============

Our study does not suggest that there is a greater prevalence of RE among overweight children. There was no dose-response relationship between GERD symptoms and increasing BMI category. However the analyses did reveal that the overweight subjects on antireflux therapy had a significantly higher prevalence of biopsy-proven RE as compared to the overweight subjects not taking antireflux medications. This finding may suggest that higher-BMI patients with symptomatology necessitating antireflux therapy should be targeted for aggressive therapy, and weight loss should be advocated to mediate this effect.

Numerous adult studies have demonstrated a positive correlation between obesity and GERD by using clinical gastroesophageal symptoms and esophageal pH monitoring in relation to obesity \[[@B14], [@B15], [@B22]--[@B27]\]. The finding of endoscopically detected RE has been a useful endpoint in studies investigating the relationship between GERD and obesity \[[@B8], [@B22], [@B23]\]. As mentioned earlier, our study used the prevalence of RE instead of symptomatology or endoscopic appearance consistent with GERD.

Our study did not support the positive relationship between BMI and GERD in children and adolescents, it is consistent with the findings published by Elitsur et al. \[[@B17]\]. Several theories may help to explain the lack of direct correlation between increasing BMI and RE in our pediatric sample. The cumulative length of time of esophageal acid exposure may be greater in adults with long-standing overweight, as compared to in children, leading to more clinically relevant GERD symptoms and greater mucosal damage and esophagitis. Since overweight subjects are at higher risk of developing both acid and nonacid reflux diseases \[[@B28]\], the use of multichannel intraluminal impedance (MII) monitoring may be useful to investigate this relationship in future prospective trials.

High percentage of our patients (56.1%) was using antireflux medications at the time of endoscopy and it is conceivable that we could have underestimated the true prevalence of RE in our population, both the overweight and normal weight groups. We did not exclude patients with confounding factors that are known to increase the risk of developing GERD, such as those with neuromuscular disorders, Down syndrome, and chronic pulmonary conditions. We did not perform pH probe study or MII monitoring to detect acid reflux as well as nonacid reflux since this was a retrospective study. Furthermore, given the reliability of waist circumference as a marker of visceral adiposity, it may have been more favorable to utilize this measure to investigate the relationship between overweight and GERD.

In summary, our study showed no significant difference in the prevalence of biopsy-proven RE in the overweight group compared to the normal weight group in children. However, future prospective trials utilizing tools to measure acid as well as non-acid reflux (such as MII) may be useful to better understand this relationship.

###### 

Characteristics of study population.

  Characteristics                           Number of patients
  ----------------------------------------- --------------------
  *Study population*                        230
                                            
  *Age*                                     
   2--10 years                              97 (42.2%)
   11--19 years                             133 (57.8%)
                                            
  *Gender*                                  
   Female                                   116 (50.4%)
   Male                                     114 (49.6%)
                                            
  *Indications*                             
   Abdominal pain                           151 (65.7%)
   Clinical GERD symptoms                   51 (22.2%)
   Weight loss                              18 (7.8%)
   Other (UGI bleeding, Crohn\'s disease)   8 (3.5%)
   Rule out allergy                         2 (0.8%)
                                            
  *BMI*                                     
   Normal BMI (5%--85%ile)                  163 (70.9%)
   At risk for overweight (85--95%ile)      29 (12.6%)
   Overweight (\>95%ile)                    38 (16.5%)
                                            
  *RE*                                      
   No                                       174 (75.7%)
   Yes                                      56 (24.3%)
                                            
  *Antireflux medication use*               
   No                                       101 (43.9%)
   Yes                                      129 (56.1%)

###### 

Comparison between BMI group and presence of RE.

                   Normal BMI   Overweight   *P*-value
  ---------------- ------------ ------------ -----------
  Presence of RE                             
   No              123          51           .916
   Yes             40 (24.5%)   16 (23.9%)   

###### 

Comparison of RE based on antireflux medication use and BMI group.

                                            RE   *P*-value    
  ----------------------------------------- ---- ------------ ------
  *Medication use in normal weight group*                     
   No                                       58   17 (22.7%)   .607
   Yes                                      65   23 (26.1%)   
                                                              
  *Medication use in overweight group*                        
   No                                       24   2 (7.7%)     .009
   Yes                                      27   14 (34.1%)   

###### 

Prevalence of RE and overweight based on age group.

                 2--10 years   11--19 years   *P*-value
  -------------- ------------- -------------- -----------
  *RE*                                        
   No            66            108            .022
   Yes           31 (32.0%)    25 (18.8%)     
                                              
  *Overweight*                                
   No            60            103            .010
   Yes           37 (38.1%)    30 (22.6%)     
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